According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that:
- SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F);
- SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX;
- SLK’s distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and
- based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
